Cidmus 50mg Tablet 14

Dr. Reddys Laboratories Ltd

Strip of 14 Units

MRP ₹446.5

₹361.08

₹31.89/Units

19.13% off applied
*MRP inclusive of all taxes
Get it By
Change
Choose your location

Use your current location

Login to view saved addresses

100% genuine medicines

Safe & secure payments

15 days Easy returns

Prescription required for this medicine

Store Below 30o C

About Cidmus 50mg Tablet 14

Cidmus 50 Tablet is a combination medication belonging to the group of medicines known as angiotensin receptor neprilysin inhibitors and angiotensin receptor blockers. It is prescribed for heart failure and improves cardiac function, ultimately enhancing patients' overall quality of life.

Before using the Cidmus 50 Tablet, inform your doctor if you have an allergy to any of the components of this medicine. This information is essential to avoid any complications during the treatment.

Last Updated On 06 Jan. 2024 | 3:12PM (IST)

Certified Content

Written by

Amatul Ameen
Amatul Ameen

Clinical Health & Medical Writer | 12 years

B. Pharm, MSc.

Reviewed by

Dr. Betina Chandolia
Dr. Betina Chandolia

Medical Content Manager | 10 years

BDS, MDS, PGCCL, PGDMH

Check out Editorial Policy

References

1. Highlights of prescribing information adjust adult doses every 2 to 4 ... (n.d.-b). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf 

2. Sacubitril-Valsartan - StatPearls - NCBI Bookshelf. (n.d.-c). https://www.ncbi.nlm.nih.gov/books/NBK507904/ 

3. Cipla Ltd. Azmarda Tablets (Sacubitril/Valsartan). Ciplamed. [Revised in March 2017] https://www.ciplamed.com/content/azmarda-tablets 

4. KD Tripathi MD. Cardiovascular drugs. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, May 2013. Page – 508.

5. Loretta Fala. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. NCBI; PMC. Pubmed Central. National Library of Medicine, National Institute of Health. September 2018. [cited 2023 July 21]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636283/  

6. Peter Khalil, Ghazal Kabbach, Sarmad Said and Debabrata Mukherje. Entresto, a New Panacea for Heart Failure. NIH National Library of Medicine, National centre for biotechnology information. Pubmed.gov. 2018. [cited 2023 July 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/29532764/  

Was this product description useful?
6 people find this information helpful

Disclaimer

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.

Recommended Substitute

62.14% CHEAPER

Lastavin S 50 MG Tablet 14
Lastavin S 50 MG Tablet 14

Ajanta Pharma Ltd

Strip of 14 Units

₹169.06

₹12.08/Units

userBought

7151 users bought this instead

Subscribe

Claim your complimentary health and fitness tips subscription and stay updated on our newest promotions.

Download Truemeds

Manage your health with ease Download Truemeds today!Get easy access to medicine refills, health information, and more. With our app, you'll never have to wait in line again. Download now and start taking control of your health.

playstoreIcon

Contact Us

Our customer representative team is available 7 days a week from 9 am - 9 pm.


v3.3.6

copyright2024 - Truemeds | All rights reserved

Our Payment Partners

paymentPartnerpaymentPartnerpaymentPartnerpaymentPartnerpaymentPartner
paymentPartnerpaymentPartnerpaymentPartnerpaymentPartner